Acamprosate to Reduce Symptoms of Alcohol Withdrawal

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Alcohol-Related DisordersAlcohol DependenceAlcoholismHealthy Volunteer
Interventions
PROCEDURE

NMR-spectroscopy

Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.

DRUG

Oral acamprosate

For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00106106 - Acamprosate to Reduce Symptoms of Alcohol Withdrawal | Biotech Hunter | Biotech Hunter